302 Results

People

  1. Motzer
    Motzer
  2. Kris
    Kris
  3. Drilon
    Drilon
  4. Zelenetz
    Zelenetz
  5. Gerecitano
    Gerecitano
  6. Horwitz
    Horwitz
  7. Hudis
    Hudis
  8. Miller
    Miller
  9. Moskowitz
    Moskowitz
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (210)
  2. Solid Tumor Oncology Division (127)
  3. Hematologic Malignancies, Division of (81)
  4. Center for Hematologic Malignancies (70)
  5. Genitourinary Oncology Service (39)
  6. Epidemiology and Biostatistics (37)
  7. GSK Faculty (35)
  8. Survivorship Research (34)
  9. Biostatistics Service (32)
  10. Radiology, Department of (31)
  1. "coughing"
Formats
  1. Journal Article (285)
  2. Review (7)
  3. Research Letter (5)
  4. Editorial (2)
  5. Conference Paper (1)
  6. Correspondence (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (210)
  2. Solid Tumor Oncology Division (127)
  3. Hematologic Malignancies, Division of (81)
  4. Center for Hematologic Malignancies (70)
  5. Genitourinary Oncology Service (39)
  6. Epidemiology and Biostatistics (37)

More Groups

People
  1. Robert Motzer (22)
  2. Mark Kris (12)
  3. Alexander Drilon (9)
  4. Andrew Zelenetz (9)
  5. Clifford Hudis (8)
  6. John Gerecitano (8)

More People

Years
  1. 2025 (9)
  2. 2024 (24)
  3. 2023 (25)
  4. 2022 (18)
  5. 2021 (14)
  6. 2020 (30)

More Years

Publications
  1. Lancet Oncology (23)
  2. Clinical Cancer Research (22)
  3. Journal of Clinical Oncology (16)
  4. New England Journal of Medicine (15)
  5. Blood (13)
  6. Cancer (13)

More Publications

Publishers
  1. Elsevier Inc. (52)
  2. Elsevier Science, Inc. (37)
  3. American Association for Cancer Research (23)
  4. Nature Publishing Group (21)
  5. Wiley Blackwell (18)
  6. American Society of Clinical Oncology (17)

More Publishers

Results (302)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First report of thoracic carcinoma with DEK::AFF2 rearrangement: A case report
    Journal Article

    Savari, O.; Chang, J. C.; Bishop, J. A.; Sakthivel, M. K.; Askin, F. B.; Rekhtman, N.
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • Telaglenastat plus everolimus in advanced renal cell carcinoma: A randomized, double-blinded, placebo-controlled, phase II ENTRATA trial
    Journal Article

    Lee, C. H.; Motzer, R.; Emamekhoo, H.; Matrana, M.; Percent, I.; Hsieh, J. J.; Hussain, A.; Vaishampayan, U.; Liu, S.; McCune, S.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: Clinical and immunologic analyses from the randomized phase 2 PRINCE trial
    Journal Article

    Padrón, L. J.; Maurer, D. M.; O’Hara, M. H.; O’Reilly, E. M.; Wolff, R. A.; Wainberg, Z. A.; Ko, A. H.; Fisher, G.; Rahma, O.; Lyman, J. P.; more...
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • Simplified graded infusion strategy for mitigation of oxaliplatin hypersensitivity
    Journal Article

    Alonso Martinez, S.; Segal, N. H.; Cercek, A.; Yaeger, R.; Stadler, Z.; Kemeny, N. E.; Nusrat, M.; Shahrokni, A.; Connell, L.; Saltz, L. B.
    Clinical Colorectal Cancer (2022)

    Fulltext@MSK | Save
  • EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: A multicentre, open-label, phase 2 study
    Journal Article

    Zauderer, M. G.; Szlosarek, P. W.; Le Moulec, S.; Popat, S.; Taylor, P.; Planchard, D.; Scherpereel, A.; Koczywas, M.; Forster, M.; Cameron, R. B.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Bilateral regional nodal irradiation using volumetric modulated arc therapy: Dosimetric analysis and feasibility
    Journal Article

    Bernstein, M. B.; Walker, K.; Gillespie, E.; Mueller, B.; Cuaron, J.; Xu, A.; McCormick, B.; Khan, A.; Cahlon, O.; Powell, S.; more...
    Practical Radiation Oncology (2022)

    Fulltext@MSK | Save
  • Feasibility of combining the phosphatidylinositol 3-kinase inhibitor copanlisib with rituximab-based immunochemotherapy in patients with relapsed indolent B-cell lymphoma
    Journal Article

    Matasar, M. J.; Dreyling, M.; Leppä, S.; Santoro, A.; Pedersen, M.; Buvaylo, V.; Fletcher, M.; Childs, B. H.; Zinzani, P. L.
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Association of varying clinical manifestations and positive anti-SARS-CoV-2 IgG antibodies: A cross-sectional observational study
    Journal Article

    Silverberg, J. I.; Zyskind, I.; Naiditch, H.; Zimmerman, J.; Glatt, A. E.; Pinter, A.; Theel, E. S.; Joyner, M. J.; Hill, D. A.; Lieberman, M. R.; more...
    Journal of Allergy and Clinical Immunology: In Practice (2021)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study
    Editorial

    Modi, S.
    Future Oncology (2021)

    Fulltext@MSK | Save
  • CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): An open-label dose-finding and first-in-human study
    Journal Article

    Naing, A.; Thistlethwaite, F.; de Vries, E. G. E.; Eskens, F. A. L. M.; Uboha, N.; Ott, P. A.; LoRusso, P.; Garcia-Corbacho, J.; Boni, V.; Bendell, J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save